Pure Global

GENPRODUCTS COMPANY SAS - Authorized Company ProfileGENPRODUCTS COMPANY SAS

Explore comprehensive authorized company profile for GENPRODUCTS COMPANY SAS through Pure Global AI's free Colombia medical device database. This company manufactures 121 medical devices registered with INVIMA across 4 risk classes. Their registration history spans from Nov 03, 2025 to Dec 01, 2033.

This page provides detailed insights including recent registrations, risk class distribution (I: 70, II: 30, Unspecified: 17, and more), and complete regulatory information from the official Colombia INVIMA medical device database with bilingual Spanish/English support. Pure Global AI offers free access to Colombia's complete medical device registry.

Free Authorized Company Profile
Powered by Pure Global AI
121 Devices
4 Risk Classes
GENPRODUCTS COMPANY SAS
GENPRODUCTS COMPANY SAS
Authorized Company
121
Total Devices
4
Risk Classes
2025
Earliest
2033
Latest
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Recent Registrations
Latest 20 INVIMA device registrations

SALSA® MS-MLPA® PROBEMIX ME011 MISMATCH REPAIR GENES

SALSA® MS-MLPA® PROBEMIX ME011 MISMATCH REPAIR GENES

dabe28b99c63de1b74bfe1765fe03e75

II

8. SALSA® MLPA® PROBEMIX P338-B2 GBA

8. SALSA® MLPA® PROBEMIX P338-B2 GBA

8dbcdec4f5cfca752f25d64886b6df95

I
Dec 01, 2033

16. SALSA® MLPA® PROBEMIX P089-B2 TK2

16. SALSA® MLPA® PROBEMIX P089-B2 TK2

0cd76bc06b40e05bb3e577b451b1157c

I
Dec 01, 2033

19. SALSA® MLPA® PROBEMIX P125-C1 MITOCHONDRIAL DNA

19. SALSA® MLPA® PROBEMIX P125-C1 MITOCHONDRIAL DNA

7cf1cefdc4a761ef42dd6bac3333a622

I
Dec 01, 2033

6. SALSA® MLPA® PROBEMIXES P321-B3/P322-C3 VPS13B

6. SALSA® MLPA® PROBEMIXES P321-B3/P322-C3 VPS13B

dc5c7c5c06bba0e1139f7a771b5e31fb

I
Dec 01, 2033

5. SALSA® MS-MLPA® PROBEMIX ME030-C3 BWS/RSS

5. SALSA® MS-MLPA® PROBEMIX ME030-C3 BWS/RSS

8518b3271006e7383b871f4a8a591bef

I
Dec 01, 2033

17. SALSA® MLPA® PROBEMIX P186-C3 PAX3 MITF SOX10

17. SALSA® MLPA® PROBEMIX P186-C3 PAX3 MITF SOX10

a0caa2b9042d4441960c4f3d1d4714f7

I
Dec 01, 2033

14. SALSA® MS-MLPA® PROBEMIX ME029-B3 FMR1/AFF2

14. SALSA® MS-MLPA® PROBEMIX ME029-B3 FMR1/AFF2

8f1b1e233aefc2026e936fc1d0533082

I
Dec 01, 2033

3. SALSA® MLPA® PROBEMIX P059-B2 DYSTONIA

3. SALSA® MLPA® PROBEMIX P059-B2 DYSTONIA

4da0d98182dacd469e355d21563b97ad

I
Dec 01, 2033

4. SALSA® MS-MLPA® PROBEMIX ME012-A1 MGMT-IDH1-IDH2

4. SALSA® MS-MLPA® PROBEMIX ME012-A1 MGMT-IDH1-IDH2

7fede733eb451b0bb73aa6760d5c3df0

I
Dec 01, 2033

10. SALSA® MLPA® PROBEMIX P067 PTCH1

10. SALSA® MLPA® PROBEMIX P067 PTCH1

b8bbf83fe654ad1e017ffa118a572b0f

I
Dec 01, 2033

12. SALSA® MLPA® PROBEMIX P076-B3 ACADVL-SLC22A5

12. SALSA® MLPA® PROBEMIX P076-B3 ACADVL-SLC22A5

46f0c1b40966fa938230f66c6fe60775

I
Dec 01, 2033

11. SALSA® MLPA® PROBEMIX P262-B2 GHI

11. SALSA® MLPA® PROBEMIX P262-B2 GHI

4f73d541fc9926ffe24b0866dc11a77e

I
Dec 01, 2033

13. SALSA® MLPA® PROBEMIX P459-A2 SERPINA1

13. SALSA® MLPA® PROBEMIX P459-A2 SERPINA1

89ef88d758a858df872c29a16964f2ff

I
Dec 01, 2033

18. SALSA® MLPA® PROBEMIX P298-A1 BRAF-HRAS-KRAS-NRAS

18. SALSA® MLPA® PROBEMIX P298-A1 BRAF-HRAS-KRAS-NRAS

bba012dbfb7ccf42be64e00a7ffc01c2

I
Dec 01, 2033

15. SALSA® MLPA® PROBEMIX P446-A2 GALC

15. SALSA® MLPA® PROBEMIX P446-A2 GALC

3779fb3ccd0f68ee3cf586477a6c3f3b

I
Dec 01, 2033

1. SALSA® MLPA® PROBEMIX P355-B1 MICROCEPHALY

1. SALSA® MLPA® PROBEMIX P355-B1 MICROCEPHALY

03760302377ea407a1d82a6f23a6576d

Dec 01, 2033

2. SALSA® MLPA® PROBEMIX P202-C1 IKZF1-ERG

2. SALSA® MLPA® PROBEMIX P202-C1 IKZF1-ERG

551cae2ceeb9080dd6056469986a6967

I
Dec 01, 2033

20. SALSA® MLPA® PROBEMIX P327-B2 IAMP21-ERG

20. SALSA® MLPA® PROBEMIX P327-B2 IAMP21-ERG

1090c44dc67317cb81bc2efca9da709b

I
Dec 01, 2033

7. SALSA® MLPA® PROBEMIX P209-C2 GLYCINE ENCEPHALOPATHY

7. SALSA® MLPA® PROBEMIX P209-C2 GLYCINE ENCEPHALOPATHY

37c61f2e34c8fdf0a0e5bcfe36de5c33

I
Dec 01, 2033
Risk Class Distribution
Devices by risk class
I
70
57.9% of total
II
30
24.8% of total
Unspecified
17
14.0% of total
III
4
3.3% of total